Ocata Therapeutics

Biotechnology, Health Care, Therapeutics
Founded in 1994-01-01
Marlborough, Massachusetts, United States
http://www.ocata.com
For Profit

About Ocata Therapeutics

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.

Company Metrics

  • Employees: 11-50
  • Monthly Visits: None
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue: Less than $1M
  • Total Funding: 42777000 USD
  • Last Funding: 10000000 USD (Post-IPO Debt)
  • Funding Status: M&A

Technology Stack

Ocata Therapeutics actively uses None products in their tech stack.

Market Presence

Industries: Biotechnology, Health Care, Therapeutics

Headquarters: Marlborough, Massachusetts, United States